Jefferies Financial Group Weighs in on Kadmon Holdings, Inc.’s FY2024 Earnings (NASDAQ:KDMN)

Kadmon Holdings, Inc. (NASDAQ:KDMN) – Equities research analysts at Jefferies Financial Group dropped their FY2024 EPS estimates for Kadmon in a research report issued on Thursday, September 9th. Jefferies Financial Group analyst C. Howerton now expects that the company will post earnings per share of $0.67 for the year, down from their previous forecast of $0.68. Jefferies Financial Group currently has a “Hold” rating and a $9.50 price target on the stock.

KDMN has been the subject of several other research reports. UBS Group downgraded Kadmon from a “buy” rating to a “neutral” rating and set a $9.50 target price on the stock. in a research report on Friday. Oppenheimer upped their target price on Kadmon from $8.00 to $9.00 and gave the stock an “outperform” rating in a report on Monday, July 19th. Raymond James downgraded shares of Kadmon from an “outperform” rating to a “market perform” rating in a report on Wednesday, September 8th. Zacks Investment Research upgraded shares of Kadmon from a “sell” rating to a “hold” rating in a report on Wednesday, August 18th. Finally, HC Wainwright restated a “buy” rating and set a $20.00 target price on shares of Kadmon in a report on Monday, August 9th. Four equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $11.83.

Kadmon stock opened at $9.02 on Monday. The company has a fifty day simple moving average of $4.95 and a 200 day simple moving average of $4.33. The company has a current ratio of 9.46, a quick ratio of 9.46 and a debt-to-equity ratio of 16.51. Kadmon has a 1-year low of $3.14 and a 1-year high of $9.20. The company has a market cap of $1.55 billion, a P/E ratio of -13.46 and a beta of 1.63.

Kadmon (NASDAQ:KDMN) last posted its earnings results on Thursday, August 5th. The company reported ($0.18) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.18). The company had revenue of $0.20 million for the quarter, compared to analyst estimates of $0.34 million. Kadmon had a negative net margin of 5,961.77% and a negative return on equity of 260.49%.

A number of hedge funds and other institutional investors have recently modified their holdings of KDMN. Point72 Asset Management L.P. raised its holdings in Kadmon by 50.0% in the 1st quarter. Point72 Asset Management L.P. now owns 11,785,115 shares of the company’s stock valued at $45,844,000 after acquiring an additional 3,927,415 shares in the last quarter. Mizuho Markets Americas LLC acquired a new stake in shares of Kadmon in the 1st quarter valued at $14,699,000. Laurion Capital Management LP boosted its holdings in shares of Kadmon by 79.7% in the 1st quarter. Laurion Capital Management LP now owns 6,493,876 shares of the company’s stock valued at $25,261,000 after purchasing an additional 2,880,792 shares in the last quarter. Morgan Stanley boosted its holdings in shares of Kadmon by 83.5% in the 1st quarter. Morgan Stanley now owns 4,074,031 shares of the company’s stock valued at $15,848,000 after purchasing an additional 1,853,277 shares in the last quarter. Finally, Jefferies Group LLC lifted its holdings in shares of Kadmon by 13,098.0% in the second quarter. Jefferies Group LLC now owns 1,443,336 shares of the company’s stock worth $5,586,000 after acquiring an additional 1,432,400 shares during the last quarter. 95.79% of the stock is currently owned by hedge funds and other institutional investors.

Kadmon Company Profile

Kadmon Holdings, Inc is a biopharmaceutical company, which engages in discovering, developing, and commercializing small molecules and biologics to address unmet medical need. The company’s clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies. The firms late-stage product candidate KD025, which is an orally administered selective inhibitor of Rho-associated coiled-coil kinase engages in development for the treatment of inflammatory and fibrotic diseases.

Featured Story: Example of operating income, EBIT and EBITDA

Earnings History and Estimates for Kadmon (NASDAQ:KDMN)

Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.